Cargando…
Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
This study investigated the frequency of adverse reactions to COVID-19 vaccines in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions. Individuals who received an mRNA COVID-19 vaccine at our center in March or April 2021 were included. Data were collected using qu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416330/ https://www.ncbi.nlm.nih.gov/pubmed/36016120 http://dx.doi.org/10.3390/vaccines10081232 |
_version_ | 1784776453774114816 |
---|---|
author | Goda, Ken Kenzaka, Tsuneaki Yahata, Shinsuke Okayama, Masanobu Nishisaki, Hogara |
author_facet | Goda, Ken Kenzaka, Tsuneaki Yahata, Shinsuke Okayama, Masanobu Nishisaki, Hogara |
author_sort | Goda, Ken |
collection | PubMed |
description | This study investigated the frequency of adverse reactions to COVID-19 vaccines in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions. Individuals who received an mRNA COVID-19 vaccine at our center in March or April 2021 were included. Data were collected using questionnaires. The main factors were age (<40, 40–59, and >60 years), sex, underlying disease, and first-dose adverse reaction. The primary outcomes were incidence of local and systemic adverse reactions (ARs) attributable to the vaccine. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Among 671 participants, 90% experienced local or systemic ARs. An AR to the first dose was associated with a significantly increased risk of an AR to the second dose (OR: 49.63, 95% CI: 21.96–112.16). ARs were less common among men than among women (OR: 0.36, 95% CI: 0.17–0.76). Local ARs were less common among those aged 60 years or older (OR: 0.35, 95% CI: 0.18–0.66), whereas systemic ARs were more common among those aged under 40 years. Information on ARs to the first dose is important for healthcare providers and recipients when making vaccination decisions. |
format | Online Article Text |
id | pubmed-9416330 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94163302022-08-27 Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine Goda, Ken Kenzaka, Tsuneaki Yahata, Shinsuke Okayama, Masanobu Nishisaki, Hogara Vaccines (Basel) Article This study investigated the frequency of adverse reactions to COVID-19 vaccines in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions. Individuals who received an mRNA COVID-19 vaccine at our center in March or April 2021 were included. Data were collected using questionnaires. The main factors were age (<40, 40–59, and >60 years), sex, underlying disease, and first-dose adverse reaction. The primary outcomes were incidence of local and systemic adverse reactions (ARs) attributable to the vaccine. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Among 671 participants, 90% experienced local or systemic ARs. An AR to the first dose was associated with a significantly increased risk of an AR to the second dose (OR: 49.63, 95% CI: 21.96–112.16). ARs were less common among men than among women (OR: 0.36, 95% CI: 0.17–0.76). Local ARs were less common among those aged 60 years or older (OR: 0.35, 95% CI: 0.18–0.66), whereas systemic ARs were more common among those aged under 40 years. Information on ARs to the first dose is important for healthcare providers and recipients when making vaccination decisions. MDPI 2022-07-31 /pmc/articles/PMC9416330/ /pubmed/36016120 http://dx.doi.org/10.3390/vaccines10081232 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Goda, Ken Kenzaka, Tsuneaki Yahata, Shinsuke Okayama, Masanobu Nishisaki, Hogara Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine |
title | Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine |
title_full | Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine |
title_fullStr | Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine |
title_full_unstemmed | Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine |
title_short | Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine |
title_sort | association between adverse reactions to the first and second doses of covid-19 vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416330/ https://www.ncbi.nlm.nih.gov/pubmed/36016120 http://dx.doi.org/10.3390/vaccines10081232 |
work_keys_str_mv | AT godaken associationbetweenadversereactionstothefirstandseconddosesofcovid19vaccine AT kenzakatsuneaki associationbetweenadversereactionstothefirstandseconddosesofcovid19vaccine AT yahatashinsuke associationbetweenadversereactionstothefirstandseconddosesofcovid19vaccine AT okayamamasanobu associationbetweenadversereactionstothefirstandseconddosesofcovid19vaccine AT nishisakihogara associationbetweenadversereactionstothefirstandseconddosesofcovid19vaccine |